FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD

GT005 is a recombinant, non-replicating AAV2 expressing human complement factor I (CFI). GT005 was administered as a single time subretinal injection into the study eye of subjects allocated to one of the two GT005 doses.

"GT005 is a recombinant, non-replicating AAV2 expressing human complement factor I (CFI).~A single dose of GT005 was administered with subretinal injection via suprachoroidal cannulation approach.~Device: Orbit™ Subretinal Delivery System"